This is an info Alert.
  • Home
  • Product
  • Blog
  • Contact

Discover laboratory and life science products for your research. Search our catalog by product name, keyword or catalog number and find the right solution for your laboratory.

Search thousands of research products

Product information & research resources

Support for your product inquiries

Products
All productsSearch products
Resources
ArticlesFAQs
Company
About usContact us
Legal
Terms & conditionsPrivacy policy

© 2026 Gentaur. All rights reserved.
ProductsArticlesContact
0
  1. Home
  2. Products
  3. ITPA Recombinant Rabbit Monoclonal Antibody [JE61-67]
1/0

ITPA Recombinant Rabbit Monoclonal Antibody [JE61-67]

Product ID: 8228471


Gentaur Catalog Number

GTR09938066
Select size

100 µL

$726.85
​
Selected
100 µL

$726.85

1

Inosine triphosphate pyrophosphatase is an enzyme that in humans is encoded by the ITPA gene, by the rdgB gene in bacteria E.coli and the HAM1 gene in yeast S. cerevisiae. Two transcript variants encoding two different isoforms have been found for this gene. Also, at least two other transcript variants have been identified which are probably regulatory rather than protein-coding. The protein encoded by this gene hydrolyzes inosine triphosphate and deoxyinosine triphosphate to the monophosphate nucleotide and diphosphate. The enzyme possesses a multiple substrate-specificity and acts on other nucleotides including xanthosine triphosphate and deoxyxanthosine triphosphate. The encoded protein, which is a member of the HAM1 NTPase protein family, is found in the cytoplasm and acts as a homodimer. Defects in the encoded protein can result in inosine triphosphate pyrophosphorylase deficiency. The enzyme ITPase dephosphorylates ribavirin triphosphate in vitro to ribavirin monophosphate, and ITPase reduced enzymatic activity present in 30 % of humans potentiates mutagenesis in hepatitis C virus.[9] Gene variants predicting reduced predicted ITPase activity have been associated with decreased risk of ribavirin-induced anemia, increased risk of thrombocytopenia, lower ribavirin concentrations, as well as a ribavirin-like reduced relapse risk following interferon-based therapy for hepatitis C virus (HCV) genotype 2 or 3 infection.